Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA. Snyder A, et al. Among authors: hollmann tj. N Engl J Med. 2014 Dec 4;371(23):2189-2199. doi: 10.1056/NEJMoa1406498. Epub 2014 Nov 19. N Engl J Med. 2014. PMID: 25409260 Free PMC article.
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD. Rizvi H, et al. J Clin Oncol. 2018 Mar 1;36(7):633-641. doi: 10.1200/JCO.2017.75.3384. Epub 2018 Jan 16. J Clin Oncol. 2018. PMID: 29337640 Free PMC article.
Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A.
Pourmaleki M, Young JH, Socci ND, Chiang S, Edelweiss M, Li Y, Zhang M, Roshal L, Chi DS, Busam KJ, Mellinghoff IK, Hollmann TJ. Pourmaleki M, et al. Among authors: hollmann tj. Oncotarget. 2019 Oct 22;10(58):6152-6167. doi: 10.18632/oncotarget.27247. eCollection 2019 Oct 22. Oncotarget. 2019. PMID: 31692889 Free PMC article.
Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy.
Jiménez-Sánchez A, Cybulska P, Mager KL, Koplev S, Cast O, Couturier DL, Memon D, Selenica P, Nikolovski I, Mazaheri Y, Bykov Y, Geyer FC, Macintyre G, Gavarró LM, Drews RM, Gill MB, Papanastasiou AD, Sosa RE, Soslow RA, Walther T, Shen R, Chi DS, Park KJ, Hollmann T, Reis-Filho JS, Markowetz F, Beltrao P, Vargas HA, Zamarin D, Brenton JD, Snyder A, Weigelt B, Sala E, Miller ML. Jiménez-Sánchez A, et al. Nat Genet. 2020 Jun;52(6):582-593. doi: 10.1038/s41588-020-0630-5. Epub 2020 Jun 1. Nat Genet. 2020. PMID: 32483290 Free PMC article.
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.
Zamarin D, Walderich S, Holland A, Zhou Q, Iasonos AE, Torrisi JM, Merghoub T, Chesebrough LF, Mcdonnell AS, Gallagher JM, Li Y, Hollmann TJ, Grisham RN, Erskine CL, Block MS, Knutson KL, O'Cearbhaill RE, Aghajanian C, Konner JA. Zamarin D, et al. Among authors: hollmann tj. J Immunother Cancer. 2020 Jun;8(1):e000829. doi: 10.1136/jitc-2020-000829. J Immunother Cancer. 2020. PMID: 32503949 Free PMC article. Clinical Trial.
Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma.
Pourmaleki M, Jones CJ, Ariyan CE, Zeng Z, Pirun M, Navarrete DA, Li Y, Zhang M, Nandakumar S, Campos C, Nadeem S, Klimstra DS, Temple-Oberle CF, Brenn T, Lipson EJ, Schenk KM, Stein JE, Taube JM, White MG, Traweek R, Wargo JA, Kirkwood JM, Gasmi B, Goff SL, Corwin AD, McDonough E, Ginty F, Callahan MK, Schietinger A, Socci ND, Mellinghoff IK, Hollmann TJ. Pourmaleki M, et al. Among authors: hollmann tj. Cancer Immunol Res. 2022 Mar 1;10(3):303-313. doi: 10.1158/2326-6066.CIR-21-1083. Cancer Immunol Res. 2022. PMID: 35013003 Free PMC article.
Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series.
Sia TY, Manning-Geist B, Gordhandas S, Murali R, Marra A, Liu YL, Friedman CF, Hollmann TJ, Zivanovic O, Chi DS, Weigelt B, Konner JA, Zamarin D. Sia TY, et al. Among authors: hollmann tj. Int J Gynecol Cancer. 2022 Aug 1;32(8):1017-1024. doi: 10.1136/ijgc-2022-003430. Int J Gynecol Cancer. 2022. PMID: 35545291 Free PMC article.
Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer.
Vanguri RS, Fenn KM, Kearney MR, Wang Q, Guo H, Marks DK, Chin C, Alcus CF, Thompson JB, Leu CS, Hibshoosh H, Kalinsky KM, Mathews JC, Nadeem S, Hollmann TJ, Connolly EP. Vanguri RS, et al. Among authors: hollmann tj. Clin Breast Cancer. 2022 Aug;22(6):538-546. doi: 10.1016/j.clbc.2022.04.002. Epub 2022 Apr 18. Clin Breast Cancer. 2022. PMID: 35610143 Free PMC article.
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer.
Vanguri RS, Luo J, Aukerman AT, Egger JV, Fong CJ, Horvat N, Pagano A, Araujo-Filho JAB, Geneslaw L, Rizvi H, Sosa R, Boehm KM, Yang SR, Bodd FM, Ventura K, Hollmann TJ, Ginsberg MS, Gao J; MSK MIND Consortium; Hellmann MD, Sauter JL, Shah SP. Vanguri RS, et al. Among authors: hollmann tj. Nat Cancer. 2022 Oct;3(10):1151-1164. doi: 10.1038/s43018-022-00416-8. Epub 2022 Aug 29. Nat Cancer. 2022. PMID: 36038778 Free PMC article.
97 results